Phase 2
Completed N=10
Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
Spinal Cord Injuries · Tetraplegia · Paraplegia · Muscle Loss
Source: ClinicalTrials.gov NCT05776862 ↗
Enrolled (actual)
10
Serious AEs
10.0%
Results posted
May 2025
Primary outcomePrimary: Change in Muscle Mass Using Dual X-ray Absorptiometry (DXA) — -183.00; 1434.00 grams
Summary
This study will evaluate if Ursolic Acid supplementation may be effective in reducing muscle loss and improving blood sugar control in the SCI community.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Muscle Mass Using Dual X-ray Absorptiometry (DXA) |
-183.00; 1434.00 | — |
| PRIMARY Changes in Peak Isokinetic Strength |
5.58; 1.83; 3.05; 9.63 | — |
| PRIMARY Changes in Fasting Insulin Resistance (IR) |
1.6125 | — |
| PRIMARY Changes in Glucose Disposal |
930.75 | — |
Eligibility Criteria
Inclusion Criteria
- Male and female individuals with paraplegia having chronic (> 1 year) motor-complete and incomplete (AIS A/B/C) injuries from T2-T8
- Male and female individuals wi4.th chronic (> 1 year) motor-complete and incomplete (AIS A/B/C) injuries from C4-C7
Exclusion Criteria
- Pregnant or planning to become pregnant
- Women who are breastfeeding
Data sourced from ClinicalTrials.gov (NCT05776862). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.